Autotelic Bio signed an MOU for business cooperation of the development of ATB-101, a fixed dose combination for the treatment of hypertension and diabetes, in the United States and strategic investment with Dream CIS and Tigermed, global Contract Research Organizations (CRO), at Bio USA 2023 held in Boston this June. The MOU signing ceremony was attended not only by Autotelic Bio but also by Dream CIS and Tigermed, the parent company of Dream CIS, raising expectations for global new drug development.  

By signing the MOU, three companies will collaborate jointly for the development of Autotelic Bio's ATB-101 in US. Additionally, the two companies plan to proceed with strategic investments in Autotelic Bio.